104 related articles for article (PubMed ID: 25179593)
21. Therapeutic Applications of Resveratrol in Hepatic Encephalopathy through Its Regulation of the Microbiota, Brain Edema, and Inflammation.
Kim YK; Song J
J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501267
[TBL] [Abstract][Full Text] [Related]
22. Alteration of Gut Microbiota and Its Impact on Immune Response in Patients with Chronic HBV Infection: A Review.
Kassa Y; Million Y; Gedefie A; Moges F
Infect Drug Resist; 2021; 14():2571-2578. PubMed ID: 34262302
[TBL] [Abstract][Full Text] [Related]
23. The gut microbiome and arsenic-induced disease-iAs metabolism in mice.
Yang Y; Chi L; Lai Y; Hsiao YC; Ru H; Lu K
Curr Environ Health Rep; 2021 Jun; 8(2):89-97. PubMed ID: 33852125
[TBL] [Abstract][Full Text] [Related]
24. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection.
El-Mowafy M; Elgaml A; El-Mesery M; Sultan S; Ahmed TAE; Gomaa AI; Aly M; Mottawea W
Biology (Basel); 2021 Jan; 10(1):. PubMed ID: 33451143
[TBL] [Abstract][Full Text] [Related]
25. The Role of the Gut Microbiome in Liver Cirrhosis Treatment.
Lee NY; Suk KT
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379148
[TBL] [Abstract][Full Text] [Related]
26. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?
Fukui H
Diseases; 2019 Nov; 7(4):. PubMed ID: 31726747
[TBL] [Abstract][Full Text] [Related]
27. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma.
Liu Q; Li F; Zhuang Y; Xu J; Wang J; Mao X; Zhang Y; Liu X
Gut Pathog; 2019; 11():1. PubMed ID: 30675188
[TBL] [Abstract][Full Text] [Related]
28. Gut microbiome disruption altered the biotransformation and liver toxicity of arsenic in mice.
Chi L; Xue J; Tu P; Lai Y; Ru H; Lu K
Arch Toxicol; 2019 Jan; 93(1):25-35. PubMed ID: 30357543
[TBL] [Abstract][Full Text] [Related]
29. Altered Microbiome in Patients With Cirrhosis and Complications.
Acharya C; Bajaj JS
Clin Gastroenterol Hepatol; 2019 Jan; 17(2):307-321. PubMed ID: 30099098
[TBL] [Abstract][Full Text] [Related]
30. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step.
Fukui H
J Clin Transl Hepatol; 2017 Sep; 5(3):249-260. PubMed ID: 28936406
[TBL] [Abstract][Full Text] [Related]
31. Administration of Lactobacillus salivarius LI01 or Pediococcus pentosaceus LI05 prevents CCl
Shi D; Lv L; Fang D; Wu W; Hu C; Xu L; Chen Y; Guo J; Hu X; Li A; Guo F; Ye J; Li Y; Andayani D; Li L
Sci Rep; 2017 Jul; 7(1):6927. PubMed ID: 28761060
[TBL] [Abstract][Full Text] [Related]
32. Community-Metabolome Correlations of Gut Microbiota from Child-Turcotte-Pugh of A and B Patients.
Wei X; Jiang S; Zhao X; Li H; Lin W; Li B; Lu J; Sun Y; Yuan J
Front Microbiol; 2016; 7():1856. PubMed ID: 27899923
[TBL] [Abstract][Full Text] [Related]
33. Gut Microbiota and Host Reaction in Liver Diseases.
Fukui H
Microorganisms; 2015 Oct; 3(4):759-91. PubMed ID: 27682116
[TBL] [Abstract][Full Text] [Related]
34. Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.
Tsiaoussis GI; Assimakopoulos SF; Tsamandas AC; Triantos CK; Thomopoulos KC
World J Hepatol; 2015 Aug; 7(17):2058-68. PubMed ID: 26301048
[TBL] [Abstract][Full Text] [Related]
35. Gut microbiota modulate the immune effect against hepatitis B virus infection.
Xu D; Huang Y; Wang J
Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2139-47. PubMed ID: 26272175
[TBL] [Abstract][Full Text] [Related]
36. Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis.
Chen Y; Qin N; Guo J; Qian G; Fang D; Shi D; Xu M; Yang F; He Z; Van Nostrand JD; Yuan T; Deng Y; Zhou J; Li L
BMC Genomics; 2014 Sep; 15(1):753. PubMed ID: 25179593
[TBL] [Abstract][Full Text] [Related]
37. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease.
Dubinkina VB; Tyakht AV; Odintsova VY; Yarygin KS; Kovarsky BA; Pavlenko AV; Ischenko DS; Popenko AS; Alexeev DG; Taraskina AY; Nasyrova RF; Krupitsky EM; Shalikiani NV; Bakulin IG; Shcherbakov PL; Skorodumova LO; Larin AK; Kostryukova ES; Abdulkhakov RA; Abdulkhakov SR; Malanin SY; Ismagilova RK; Grigoryeva TV; Ilina EN; Govorun VM
Microbiome; 2017 Oct; 5(1):141. PubMed ID: 29041989
[TBL] [Abstract][Full Text] [Related]
38. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach.
Wei X; Yan X; Zou D; Yang Z; Wang X; Liu W; Wang S; Li X; Han J; Huang L; Yuan J
BMC Gastroenterol; 2013 Dec; 13():175. PubMed ID: 24369878
[TBL] [Abstract][Full Text] [Related]
39. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
Zeng Y; Chen S; Fu Y; Wu W; Chen T; Chen J; Yang B; Ou Q
J Viral Hepat; 2020 Feb; 27(2):143-155. PubMed ID: 31600845
[TBL] [Abstract][Full Text] [Related]
40. Investigation of etiology-specific alterations in the gut microbiota in liver cirrhosis.
Naseri M; Houri H; Yadegar A; Asadzadeh Aghdaei H; Zahiri J
Expert Rev Gastroenterol Hepatol; 2021 Dec; 15(12):1435-1441. PubMed ID: 34632902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
